AB1479 VALIDATION OF RUSSIAN VERSION PSAID-12: ASSESSMENT OF THE RELIABILITY, CONSTRUCTIVE AND CONVERGENT VALIDITY OF THE QUESTIONNAIRE
Authors: L. Vorobyova, T. Korotaeva, E. Loginova, E. Gubar, Y. Korsakova
Journal: Annals of the Rheumatic Diseases (2022)

Background Psoriatic arthritis (PsA) is a chronic inflammatory disease of widely varying presentation, which determines functional and psychological impairment, with a high negative impact on patients’ quality of life. Therefore, knowing the patient’s perception of their health status is of fundamental importance for understanding the real impact of PsA. In recent years, a PsAID (Psoriatic Arthritis Impact of Disease) questionnaire has been developed for PsA EULAR, consisting of 9 or 12 questions related to the severity of pain, anxiety, fatigue, disability, sleep disorders, and social activity. Objectives To study, in a real-life setting, the construct and convergent validity, the reliability, and the interpretability of the Russian version PsAID-12 in patients with PsA. Methods 187 (M/F=97 (50.2%)/90(48.8%) PsA pts fulfilling the CASPAR criteria were included. Mean age 45.6±11.7 years (yrs), DAPSA 21.05±21.03, median (Me) PsA duration 88 [16;421] mo. All pts underwent standard clinical examinations and PROs (EQ-5D, PsAID12). Reliability was assessed by Cronbach’s alpha coefficient and by the intraclass correlation coefficient (ICC) for each of the 12 scales. The construct validity was evaluated by exploratory factorial analysis and also by Spearman correlation with EQ-5D and measures of disease activity evaluation. Results The reliability of ICC (alpha-Cronbach = 0.8-0.9) and test-retest (ICC 95%CI 0.85-0.96) were good. Construct validity: Factor analysis revealed a 2-factor result defined as the PsAID-12: Phisical health score and Emotional health score. A strong correlation was also found for each of the 12 scales with the questionnaire EQ-5D was strong correlation (r= -0.52 to -0.78, p&lt;0.001) In determining convergent validity, significant correlations were found between the PsAID-12 and TJC 68, SJC 66, DAPSA, VAS global assessments, VAS global pain, BASDAI. The high correlation was found between the BASDAI and the scale “Functional capacity” (r=0.8, p&lt;0.001), as well as sufficiently high correlation coefficients with parameters were noted with the scales “Pain”, “Fatigue”, “Work and/or leisure activities”, “Discomfort” and “Coping”. The lowest was observed with scales “Skin problems” and “Depression” (Table 1). Table 1. Convergent validity PsAID-12 with clinical parameters (r ) Scales TJC 68 SJC 66 DAPSA VAS global assessments VAS global pain BASDAI Pain 0,6 0,68 0,71 0,72 0,75 0,78 Fatigue 0,59 0,62 0,68 0,71 0,68 0,75 Skin problems 0,35 0,36 0,41 0,47 0,37 0,46 Work and/or leisure activities 0,57 0,62 0,68 0,75 0,71 0,67 Functional capacity 0,61 0,64 0,72 0,79 0,71 0,80 Discomfort 0,61 0,65 0,71 0,77 0,70 0,76 Sleep disturbance 0,44 0,50 0,54 0,55 0,60 0,61 Coping 0,59 0,63 0,67 0,66 0,65 0,76 Anxiety, fear and uncertainty 0,46 0,48 0,52 0,52 0,51 0,64 Embarrasment 0,47 0,49 0,51 0,48 0,41 0,52 Social participant 0,54 0,57 0,62 0,64 0,62 0,66 Depression 0,43 0,43 0,49 0,57 0,54 0,47 Conclusion The russian version of PsAID-12 has been shown to be a reliable and valid measure of the impact of the disease in patients with psoriatic arthritis. Disclosure of Interests None declared